Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 17/20 | 0.76 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapisteride SCHEMBL6808834 | 1.00 | SRD5A1 (0.76) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9022407 | 0.90 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8378899 | 0.90 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9021958 | 0.88 | SRD5A1 (0.63) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9022386 | 0.88 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9022411 | 0.85 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9022414 | 0.85 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 0.85 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 0.85 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL3982016 | 0.85 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0963998-B1 | AZASTEROID COMPOUND FOR TREATING OR PREVENTING PROSTATIC CANCER | SANKYO CO (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-0998930-B1 | AZASTEROID COMPOUND FOR TREATING ALOPECIA, HIRSUTISM AND SEBORRHEA | SANKYO CO (JP) | 2004-03-24 | — | — | EP | claimed |
| US-6380179-B1 | ADMINISTERING N-(1-METHYL-1-(4-METHOXYPHENYL)ETHYL)-3-OXO-4-AZA-5ALPHA-ANDRO ST-1-ENE-17BETA-CARBAXAMIDE | SANKYO COMPANY, LIMITED (JP) | 2002-04-30 | — | — | US | claimed |
| US-20020015732-A1 | FORMULATION OF A 5 ALPHA REDUCTASE INHIBITOR FOR ORAL ADMINISTRTION, AND A PREPARATION PROCESS AND USE THEREOF | SANKYO COMPANY, LIMITED (JP) | 2002-02-07 | — | — | US | claimed |
| EP-0923942-B1 | 5alpha-REDUCTASE INHIBITORY PREPARATION FOR ORAL ADMINISTRATION, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | SANKYO CO (JP) | 2001-11-14 | — | — | EP | claimed |
| US-6251915-B1 | ADMINISTERING TO MALE WARM-BLOODED ANIMAL ANTI-CANCER AGENT COMPRISING N-(1-METHYL-1-(4-METHOXYPHENYL)ETHYL)-3-OXO-4-AZA-5.ALPHA. -ANDROST-1-ENE-17.BETA.-CARBOXAMIDE OR ITS SALT OR ESTER | SANKYO COMPANY, LIMITED (JP) | 2001-06-26 | — | — | US | claimed |
| EP-0998930-A1 | REMEDIAL AGENT FOR BALDNESS AND OTHER DISEASES | Sankyo Company Limited (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0963998-A1 | COMPOSITIONS FOR TREATING OR PREVENTING PROSTATIC CANCER | Sankyo Company Limited (JP) | 1999-12-15 | — | — | EP | claimed |
| EP-0923942-A1 | 5alpha-REDUCTASE INHIBITORY PREPARATION FOR ORAL ADMINISTRATION, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Sankyo Company, Limited (JP) | 1999-06-23 | — | — | EP | claimed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | claimed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | claimed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | claimed |
| JP-10298081-A | — | — | None | — | — | JP | disclosed |
| US-11696883-B2 | Compositions for reducing hair loss and/or increasing hair regrowth | TRIPLE HAIR INC. (CA) | 2023-07-11 | — | — | US | disclosed |
| US-20160346183-A1 | Compositions for Reducing Hair Loss And/Or Increasing Hair Regrowth | Triple Hair, Inc. (CA) | 2016-12-01 | — | — | US | disclosed |
| EP-0963998-B1 | AZASTEROID COMPOUND FOR TREATING OR PREVENTING PROSTATIC CANCER | SANKYO CO (JP) | 2004-05-06 | — | — | EP | disclosed |
| JP-H10298081-A | THERAPEUTIC OR PREVENTIVE AGENT FOR PROSTATIC CANCER | SANKYO CO LTD | 1998-11-10 | — | — | JP | disclosed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696883-B2 | Compositions for reducing hair loss and/or increasing hair regrowth | AR, PTGIR, MC1R | SRD5A1 8/4885SRD5A2 9/4885LMNA 3241/4885 |
| US-20020015732-A1 | FORMULATION OF A 5 ALPHA REDUCTASE INHIBITOR FOR ORAL ADMINISTRTION, AND A PREPARATION PROCESS AND USE THEREOF | SRD5A1, SRD5A2, CYP17A1 | SRD5A1 1/4885SRD5A2 2/4885LMNA 2955/4885 |
| US-20160346183-A1 | Compositions for Reducing Hair Loss And/Or Increasing Hair Regrowth | AR, PTGIR, MC1R | SRD5A1 8/4885SRD5A2 9/4885LMNA 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.